HBIO — Harvard Bioscience Share Price
0.000.00%
Last trade - 00:00- $160.66m
- $192.94m
- $112.25m
- 68
- 60
- 29
- 51
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 15.79 | ||
| PEG Ratio (f) | 0.17 | ||
| EPS Growth (f) | 1,850.79% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.2 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 13.71 | ||
| Price to Sales | 1.43 | ||
| EV to EBITDA | 21.7 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 1.71% | ||
| Return on Equity | -4.7% | ||
| Operating Margin | 1.69% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 116.18 | 102.1 | 118.9 | 113.33 | 112.25 | 114.87 | 125.55 | -1.45% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +38.1 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Its products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. The CMT product family is primarily composed of products supporting research related to molecular, cellular, organ and organoid technologies. The Preclinical product family includes products that support the preclinical research and testing phase for drug development, and in particular, testing related to data collection and analysis for safety and regulatory compliance.
Directors
- James Green CHM (62)
- Michael Rossi CFO (47)
- Bertrand Loy LED (56)
- Katherine Eade IND (47)
- Alan Edrick IND (53)
- Thomas Loewald IND (58)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 8th, 2000
- Public Since
- October 21st, 2013
- No. of Shareholders
- 90
- No. of Employees
- 391
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 43,421,251
- Address
- 84 OCTOBER HILL RD, HOLLISTON, 01746
- Web
- https://www.harvardbioscience.com/
- Phone
- +1 5088938999
- Auditors
- Grant Thornton LLP
Upcoming Events for HBIO
Harvard Bioscience Inc Annual Shareholders Meeting
Harvard Bioscience Inc Annual Shareholders Meeting
Q2 2024 Harvard Bioscience Inc Earnings Release
Similar to HBIO
908 Devices.
NASDAQ Global Market
Alpha Teknova
NASDAQ Global Market
AtriCure
NASDAQ Global Market
Brainsway
NASDAQ Global Market
Castle Biosciences
NASDAQ Global Market
FAQ
What is the Harvard Bioscience share price?
As of Today at 19:10 UTC, shares in Harvard Bioscience are trading at $3.70. This share price information is delayed by 15 minutes.
How has the Harvard Bioscience share price performed this year?
Shares in Harvard Bioscience last closed at $3.70 and the price had moved by -23.55% over the past 365 days. In terms of relative price strength the Harvard Bioscience share price has underperformed the S&P500 Index by -36.38% over the past year.
What are the analyst and broker recommendations for Harvard Bioscience?
The overall consensus recommendation for Harvard Bioscience is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Harvard Bioscience dividend yield?
Harvard Bioscience does not currently pay a dividend.
Does Harvard Bioscience pay a dividend?
Harvard Bioscience does not currently pay a dividend.
When does Harvard Bioscience next pay dividends?
Harvard Bioscience does not currently pay a dividend.
How do I buy Harvard Bioscience shares?
To buy shares in Harvard Bioscience you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Harvard Bioscience?
As of the previous close price of $3.70, shares in Harvard Bioscience had a market capitalisation of $160.66m.
Where are Harvard Bioscience shares listed?
Here are the trading details for Harvard Bioscience:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: HBIO
What kind of share is Harvard Bioscience?
Based on an overall assessment of its quality, value and momentum Harvard Bioscience is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Harvard Bioscience share price forecast for 2024?
The analyst consensus target price for shares in Harvard Bioscience is $6.92. That is 87.03% above the last closing price of $3.70.
Analysts covering Harvard Bioscience currently have a consensus Earnings Per Share (EPS) forecast of $0.21 for the next financial year.
What is the trend in the Harvard Bioscience share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Harvard Bioscience. Over the past six months, its share price has underperformed the S&P500 Index by -26.61%.
As of the last closing price of $3.70, shares in Harvard Bioscience were trading -17.96% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Harvard Bioscience PE Ratio?
The Harvard Bioscience PE ratio based on its reported earnings over the past 12 months is 15.79. The shares last closed at $3.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Harvard Bioscience?
Harvard Bioscience's management team is headed by:
- James Green - CHM
- Michael Rossi - CFO
- Bertrand Loy - LED
- Katherine Eade - IND
- Alan Edrick - IND
- Thomas Loewald - IND